Acumen Pharmaceuticals (ABOS) Long-Term Investments (2021 - 2025)

Acumen Pharmaceuticals (ABOS) has 5 years of Long-Term Investments data on file, last reported at $9.4 million in Q3 2025.

• For the quarter ending Q3 2025, Long-Term Investments fell 83.87% year-over-year to $9.4 million; the trailing twelve-month figure through Sep 2025 stood at $9.4 million (down 83.87% YoY), and the FY2024 full-year result was $60.0 million, down 4.13% from the prior year.
• Long-Term Investments declined to $9.4 million in Q3 2025, from $22.8 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $67.3 million in Q3 2023 to a low of $9.4 million in Q3 2025.
• A 5-year average of $36.9 million and a median of $30.8 million in 2021 frame the typical range for Long-Term Investments.
• Across the five-year window, Long-Term Investments surged 294.98% in 2023 and tumbled 83.87% in 2025, its largest moves.
• Tracing ABOS's Long-Term Investments over 5 years: stood at $31.6 million in 2021, then plunged by 49.91% to $15.8 million in 2022, then surged by 294.98% to $62.6 million in 2023, then slipped by 4.13% to $60.0 million in 2024, then sank by 84.25% to $9.4 million in 2025.
• Business Quant data shows ABOS's Long-Term Investments at $9.4 million in Q3 2025, $22.8 million in Q2 2025, and $48.8 million in Q1 2025.